Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 30 June 2000:
Vol. 288. no. 5475, p. 2303
DOI: 10.1126/science.288.5475.2303
Prev | Table of Contents | Next

News of the Week

PATENT DISPUTES:
Biotech Giants Butt Heads Over Cancer Drug

Eliot Marshall

On 8 June, Chiron challenged Genentech's patent on an important new breast cancer drug called Herceptin and sued for a share of the profits. Chiron's 4-page complaint, filed in the federal district court in Sacramento, California, accuses Genentech of "willful, wanton, and deliberate" infringement of one of its patents. The case is being closely watched in the biotech industry not just because of the money at stake but also because it involves one of the first therapies to emerge from the burgeoning field of cancer genetics

Read the Full Text

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)